H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Genmab (Otc) (($GMAB)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled A Phase 1b/2 Open-Label ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in follicular lymphoma (FL). | Genmab and AbbVie have presented new data that could ...

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key ...

Genmab AS (GMAB) reports a 19% revenue increase and a 56% rise in operating profit, showcasing strong financial performance ...

Genmab A/S today announced changes to its Executive Committee to support Genmab’ s growth and evolution into a fully integrated biotech innovation powerhouse. Genmab’ s Executive Committee ...

Danish biotechnology company Genmab will acquire U.S. ProfoundBio for $1.8 billion in cash as it looks to bolster its pipeline of cancer treatments. The acquisition will give Genmab worldwide ...